Equities

CASI Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CASI:NAQ

CASI Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9247
  • Today's Change-0.025 / -2.66%
  • Shares traded17.36k
  • 1 Year change-65.50%
  • Beta0.8993
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

  • Revenue in USD (TTM)26.85m
  • Net income in USD-49.38m
  • Incorporated2023
  • Employees233.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bon Natural Life Ltd18.67m-1.99m10.05m96.0018.520.2302--0.53850.0880.0886.747.080.25416.071.64194,486.40-2.795.82-3.977.8620.7728.53-10.9810.831.61-4.440.17350.00-21.700.4899-577.58--18.20--
Integrated Biopharma Inc53.43m672.00k10.25m153.0015.570.500310.350.19190.02120.02121.710.65972.074.4512.77349,183.002.609.983.2813.689.7510.741.264.581.92--0.0072--8.020.5933482.30-30.67-0.8556--
Akari Therapeutics PLC (ADR)0.00-15.77m10.30m8.00---------0.600-0.6000.00--0.00----0.00-65.57-112.46-136.47-257.78-----------27.770.0854-------97.75------
Hoth Therapeutics Inc0.00-12.16m11.95m2.00--1.42-----1.06-1.060.000.54420.00----0.00-138.61-129.47-154.67-144.30-----------493.480.00-------4.37------
Cellectar Biosciences Inc0.00-18.85m11.96m11.00--1.20-----10.78-10.780.002.940.00----0.00-72.62-104.57-141.24-133.43------------0.00-------4.23--33.54--
Lexaria Bioscience Corp522.00k-10.79m16.48m7.00--2.99--31.56-0.5743-0.57430.02720.2210.0659--2.9774,571.43-136.35-102.60-145.39-105.78100.0087.95-2,069.41-1,579.38---285.300.00--52.0517.53-105.37--48.50--
LakeShore Biopharma Co Ltd88.64m-14.41m16.49m573.00--0.11532.490.186-0.7458-0.74584.633.470.4270.50011.30154,693.30-6.94---15.95--82.47---16.26--0.7452-2.630.453--7.24--76.93------
Natural Alternatives International Inc134.44m-11.88m19.21m293.00--0.2783--0.1429-1.99-1.9922.5211.170.8454.357.36458,839.60-7.470.4593-9.150.54798.5012.75-8.840.42961.01-2.560.14080.0014.121.78-88.10---4.46--
CASI Pharmaceuticals Inc26.85m-49.38m19.52m233.00------0.7271-2.98-2.981.62-1.850.60961.604.22115,218.90-107.02-36.27-277.91-51.9053.6857.36-175.56-124.010.236-13.27-----15.7747.19-45.62---55.67--
Global Pharmatech Inc.3.18m-2.24m20.76m217.00--0.1459--6.53-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Nutraproducts Inc0.00-821.94k20.92m0.00--3.50-----1.31-1.310.000.29730.00-------513.70-1,177.23-740.45-------------385.170.00--------------
Dare Bioscience Inc27.69k-17.46m24.01m21.00--8.19--866.95-1.92-1.920.00290.20520.0011--0.06241,318.57-71.56-91.64-241.96-243.93127.70---63,069.55-1,024.05---156.390.7177---99.65--86.56------
Aytu Biopharma Inc63.70m-13.31m24.69m82.00--0.9839--0.3876-2.27-2.245.932.340.5291.892.26776,780.50-11.05-26.47-23.44-47.3267.5660.56-20.90-52.541.080.34430.5398--1.8419.16-13.27------
TherapeuticsMD Inc2.80m73.00k25.35m1.00350.960.923655.109.070.00620.02610.24192.370.0715--0.80022,796,000.000.1867-42.650.2169-112.14----2.61-193.47---5,240.000.00--35.25-48.7269.97------
Medicus Pharma Ltd-100.00bn-100.00bn27.37m-----------------0.0434-----------361.95----------------1.13-------109.90------
SCYNEXIS Inc2.93m-25.30m28.97m28.00--0.7951--9.88-0.5107-0.51070.05930.86830.0391--0.5776104,714.30-33.71-20.51-43.65-24.9733.32---862.89-64.82----0.00---97.3398.68-131.75------
Data as of Feb 06 2026. Currency figures normalised to CASI Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

3.11%Per cent of shares held by top holders
HolderShares% Held
BofA Securities, Inc.as of 30 Sep 2025254.82k1.24%
Woodline Partners LPas of 30 Sep 2025165.64k0.81%
Wellington Shields Capital Management LLCas of 30 Sep 202569.54k0.34%
Renaissance Technologies LLCas of 30 Sep 202543.90k0.21%
Two Sigma Investments LPas of 30 Sep 202533.27k0.16%
Wellington Shields & Co. LLC (Investment Management)as of 30 Sep 202530.09k0.15%
Geode Capital Management LLCas of 30 Sep 202518.81k0.09%
Ground Swell Capital LLCas of 30 Sep 202510.14k0.05%
Brewin Dolphin Wealth Management Ltd.as of 30 Sep 20259.70k0.05%
Group One Trading LLCas of 30 Sep 20252.30k0.01%
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.